Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection

References

• Welsh FKS, Walsh CM, Chandrakumaran K, et al. Peri-operative thrombophilia in patients undergoing liver resection for colorectal metastases [observational study]. HPB. 2023 Jan;25(1):63–72. doi: 10.1016/j.hpb.2022.09.013
   PubMed Web of Science ®Google Scholar
• Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020 Dec;13(12):1833–1839. doi: 10.1016/j.jiph.2020.07.014
   PubMed Web of Science ®Google Scholar
• Lala A, Johnson KW, Januzzi JL, et al. Prevalence and Impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020 Aug 4;76(5):533–546. doi: 10.1016/j.jacc.2020.06.007
   PubMed Web of Science ®Google Scholar
• Nakano H, Shiina K, Tomiyama H. Cardiovascular outcomes in the acute phase of COVID-19. Int J Mol Sci. 2021 Apr 15;22(8):4071. doi: 10.3390/ijms22084071
   PubMed Web of Science ®Google Scholar
• Wang W, Wang CY, Wang SI, et al. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022 Nov;53:101619.
   PubMedGoogle Scholar
• Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Mar;28(3):583–590. doi: 10.1038/s41591-022-01689-3
   PubMed Web of Science ®Google Scholar
• Salah HM, Fudim M, O’Neil ST, et al. Post-recovery COVID-19 and incident heart failure in the National COVID cohort Collaborative (N3C) study. Nat Commun. 2022 Jul 15;13(1):4117. doi: 10.1038/s41467-022-31834-y
   PubMed Web of Science ®Google Scholar
• Giannis D, Allen SL, Tsang J, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021 May 20;137(20):2838–2847. doi: 10.1182/blood.2020010529
   PubMed Web of Science ®Google Scholar
• Tereshchenko LG, Bishop A, Fisher-Campbell N, et al. Risk of cardiovascular events after COVID-19. Am J Cardiol. 2022 Sep 15;179:102–109. doi: 10.1016/j.amjcard.2022.06.023
   PubMed Web of Science ®Google Scholar
• Wiemken TL, McGrath LJ, Andersen KM, et al. COVID-19 severity and risk of subsequent cardiovascular events. Clin Infect Dis. 2023 Feb 8;76(3):e42–e50. doi: 10.1093/cid/ciac661
   PubMed Web of Science ®Google Scholar
• Cuomo G, Puzzolante C, Iadisernia V, et al. Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study. Infez Med. 2021;29(4):538–549.
   PubMedGoogle Scholar
• Marfella R, Paolisso P, Sardu C, et al. SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction. Crit Care. 2021 Jun 24;25(1):217. doi: 10.1186/s13054-021-03643-0
   PubMed Web of Science ®Google Scholar
• Evans PC, Rainger GE, Mason JC, et al. Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science. Cardiovasc Res. 2020 Dec 1;116(14):2177–2184. doi: 10.1093/cvr/cvaa230
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Souvaliotis N, Lampsas S, et al. Endothelial dysfunction in acute and long standing COVID-19: a prospective cohort study. Vasc Pharmacol. 2022 Jun;144:106975.
   PubMed Web of Science ®Google Scholar
• Santoro L, Falsetti L, Zaccone V, et al. Impaired endothelial function in convalescent phase of COVID-19: a 3 month follow up observational prospective study. J Clin Med. 2022 Mar 23;11(7):1774. doi: 10.3390/jcm11071774
   PubMed Web of Science ®Google Scholar
• Jud P, Gressenberger P, Muster V, et al. Evaluation of endothelial dysfunction and inflammatory vasculopathy after SARS-CoV-2 infection-A cross-sectional study. Front Cardiovasc Med. 2021;8:750887. doi: 10.3389/fcvm.2021.750887
   PubMed Web of Science ®Google Scholar
• Jud P, Kessler HH, Brodmann M. Case report: changes of vascular reactivity and arterial stiffness in a patient with covid-19 infection. Front Cardiovasc Med. 2021;8:671669. doi: 10.3389/fcvm.2021.671669
   PubMed Web of Science ®Google Scholar
• Szeghy RE, Province VM, Stute NL, et al. Carotid stiffness, intima-media thickness and aortic augmentation index among adults with SARS-CoV-2. Exp Physiol. 2022 Jul;107(7):694–707. doi: 10.1113/EP089481
   PubMed Web of Science ®Google Scholar
• Ratchford SM, Stickford JL, Province VM, et al. Vascular alterations among young adults with SARS-CoV-2. Am J Physiol Heart Circ Physiol. 2021 Jan 1;320(1):H404–h410. doi: 10.1152/ajpheart.00897.2020
   PubMed Web of Science ®Google Scholar
• Kumar N, Kumar S, Kumar A, et al. The COSEVAST study outcome: evidence of COVID-19 severity proportionate to surge in arterial stiffness. Indian J Crit Care Med. 2021 Oct;25(10):1113–1119. doi: 10.5005/jp-journals-10071-24000
   PubMed Web of Science ®Google Scholar
• Pirzada A, Mokhtar AT, Moeller AD. COVID-19 and myocarditis: what do We know so far? CJC Open. 2020 Jul;2(4):278–285. doi: 10.1016/j.cjco.2020.05.005
   PubMedGoogle Scholar
• Gavriilaki E, Anyfanti P, Gavriilaki M, et al. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. Curr Hypertens Rep. 2020 Aug 27;22(9):63. doi: 10.1007/s11906-020-01078-6
   PubMed Web of Science ®Google Scholar
• D’Ardes D, Boccatonda A, Cocco G, et al. Impaired coagulation, liver dysfunction and COVID-19: discovering an intriguing relationship. World J Gastroenterol. 2022 Mar 21;28(11):1102–1112. doi: 10.3748/wjg.v28.i11.1102
   PubMed Web of Science ®Google Scholar
• Boccatonda A, Ianniello E, D’Ardes D, et al. Can lung ultrasound be used to screen for pulmonary embolism in patients with SARS-CoV-2 pneumonia? Eur J Case Rep Intern Med. 2020;7(7):001748.
   PubMedGoogle Scholar
• Degauque N, Haziot A, Brouard S, et al. Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection. FASEB J. 2021 May;35(5):e21577. doi: 10.1096/fj.202100024R
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 Jun 15;109(23 Suppl 1):Iii27–32. doi: 10.1161/01.CIR.0000131515.03336.f8
   PubMed Web of Science ®Google Scholar
• Postiga IAL, Teixeira PC, Neves CAM, et al. Systemic redox imbalance in severe COVID-19 patients. Cell Biochem Funct. 2022 Aug 18;40(7):694–705. doi: 10.1002/cbf.3735
   PubMed Web of Science ®Google Scholar
• D’Ardes D, Boccatonda A, Rossi I, et al. COVID-19 and RAS: unravelling an unclear relationship. Int J Mol Sci. 2020 Apr 24;21(8):3003. doi: 10.3390/ijms21083003
   PubMed Web of Science ®Google Scholar
• Simeone P, Boccatonda A, Liani R, et al. Significance of urinary 11-dehydro-thromboxane B(2) in age-related diseases: focus on atherothrombosis. Ageing Res Rev. 2018 Dec;48:51–78.
   PubMed Web of Science ®Google Scholar
• Lessiani G, Santilli F, Boccatonda A, et al. Arterial stiffness and sedentary lifestyle: role of oxidative stress. Vasc Pharmacol. 2016 Apr;79:1–5.
   PubMed Web of Science ®Google Scholar
• Boccatonda A, Tripaldi R, Davì G, et al. Oxidative stress modulation through habitual physical activity. Curr Pharm Des. 2016;22(24):3648–3680. doi: 10.2174/1381612822666160413123806
   PubMed Web of Science ®Google Scholar
• Andrianto A-FM, Nugraha RA, Marsudi BA, et al. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Microvasc Res. 2021 Nov;138:104224.
   PubMed Web of Science ®Google Scholar
• Lampsas S, Tsaplaris P, Pantelidis P, et al. The role of endothelial related circulating biomarkers in COVID-19. A systematic review and meta-analysis. Curr Med Chem. 2022;29(21):3790–3805. doi: 10.2174/0929867328666211026124033
   PubMed Web of Science ®Google Scholar
• Garnier Y, Claude L, Hermand P, et al. Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner. Br J Haematol. 2022 Mar;196(5):1159–1169. doi: 10.1111/bjh.18019
   PubMed Web of Science ®Google Scholar
• Centa A, Fonseca AS, Ferreira S, et al. Deregulated miRNA expression is associated with endothelial dysfunction in post-mortem lung biopsies of COVID-19 patients. Am J Physiol Lung Cell Mol Physiol. 2020 Dec 2;320(3):L405–12. doi: 10.1152/ajplung.00457.2020
   PubMed Web of Science ®Google Scholar
• Willems LH, Nagy M, Ten Cate H, et al. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res. 2022 Jan;209:106–114.
   PubMed Web of Science ®Google Scholar
• Flaskamp L, Roubal C, Uddin S, et al. Serum of post-COVID-19 syndrome patients with or without ME/CFS differentially affects endothelial cell function in vitro. Cells. 2022 Aug 2;11(15):2376. doi: 10.3390/cells11152376
   PubMed Web of Science ®Google Scholar
• Desimmie BA, Raru YY, Awadh HM, et al. Insights into SARS-CoV-2 persistence and its relevance. Viruses. 2021 May 29;13(6):1025. doi: 10.3390/v13061025
   PubMed Web of Science ®Google Scholar
• Buonsenso D, Martino L, Morello R, et al. Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies. Lancet Microbe. 2023 Sep;4(9):e745–e756. doi: 10.1016/S2666-5247(23)00115-5
   PubMedGoogle Scholar
• Eymieux S, Uzbekov R, Rouillé Y, et al. Secretory vesicles are the Principal means of SARS-CoV-2 egress. Cells. 2021 Aug 10;10(8):2047. doi: 10.3390/cells10082047
   PubMed Web of Science ®Google Scholar
• Barberis E, Vanella VV, Falasca M, et al. Circulating exosomes are strongly involved in SARS-CoV-2 infection. Front Mol Biosci. 2021;8:632290. doi: 10.3389/fmolb.2021.632290
   PubMed Web of Science ®Google Scholar
• Falconieri F, Raevsky E, Davies S, et al. Pseudoaneurysm of a branch of left internal mammary artery: a late and potentially fatal complication after redo-sternotomy. Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):866–867. doi: 10.1093/icvts/ivv059
   PubMed Web of Science ®Google Scholar
• Borowiec BM, Angelova Volponi A, Mozdziak P, et al. Small extracellular vesicles and COVID19—using the “trojan horse” to tackle the giant. Cells. 2021 Dec 1;10(12):3383. doi: 10.3390/cells10123383
   PubMed Web of Science ®Google Scholar
• Amenta EM, Spallone A, Rodriguez-Barradas MC, et al. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020 Dec;7(12):ofaa509. doi: 10.1093/ofid/ofaa509
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021 Dec 1;224(11):1839–1848. doi: 10.1093/infdis/jiab490
   PubMed Web of Science ®Google Scholar
• Fernández-Lázaro D, Sánchez-Serrano N, Mielgo-Ayuso J, et al. Long COVID a New derivative in the chaos of SARS-CoV-2 infection: the emergent pandemic? J Clin Med. 2021 Dec 11;10(24):5799. doi: 10.3390/jcm10245799
   PubMed Web of Science ®Google Scholar
• Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022 Mar;101:93–135.
   PubMed Web of Science ®Google Scholar
• Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020 Oct;26(10):1623–1635. doi: 10.1038/s41591-020-1038-6
   PubMed Web of Science ®Google Scholar
• Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021 Oct;53(10):737–754. doi: 10.1080/23744235.2021.1924397
   PubMed Web of Science ®Google Scholar
• Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021 Apr;19(4):1064–1070. doi: 10.1111/jth.15267
   PubMed Web of Science ®Google Scholar
• Pasini E, Corsetti G, Romano C, et al. Serum metabolic profile in patients with long-covid (PASC) syndrome: clinical implications. Front Med. 2021;8:714426. doi: 10.3389/fmed.2021.714426
   Google Scholar
• Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 Feb;23(2):210–216. doi: 10.1038/s41590-021-01113-x
   PubMed Web of Science ®Google Scholar
• Volpicelli G, Gargani L, Perlini S, et al. Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study. Intensive care Med. 2021 Apr;47(4):444–454. doi: 10.1007/s00134-021-06373-7
   PubMed Web of Science ®Google Scholar
• Fogarty H, Ward SE, Townsend L, et al. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost. 2022 Oct;20(10):2429–2438. doi: 10.1111/jth.15830
   PubMed Web of Science ®Google Scholar
• Buonsenso D, Valentini P, De Rose C, et al. Recovering or persisting: the immunopathological features of SARS-CoV-2 infection in children. J Clin Med. 2022 Jul 27;11(15):4363. doi: 10.3390/jcm11154363
   PubMed Web of Science ®Google Scholar
• Files JK, Sarkar S, Fram TR, et al. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight. 2021 Aug 9;6(15). doi: 10.1172/jci.insight.151544
   PubMed Web of Science ®Google Scholar
• Yao L, Wang GL, Shen Y, et al. Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection. J Infect Dis. 2021 Aug 16;224(4):586–594. doi: 10.1093/infdis/jiab255
   PubMed Web of Science ®Google Scholar
• Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021 Sep 14;12(1):5417. doi: 10.1038/s41467-021-25509-3
   PubMed Web of Science ®Google Scholar
• Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI154886
   Web of Science ®Google Scholar
• Sawadogo SA, Dighero-Kemp B, Ouédraogo DD, et al. How NETosis could drive “post-COVID-19 syndrome” among survivors. Immunol Lett. 2020 Dec;228:35–37.
   PubMed Web of Science ®Google Scholar
• Ng H, Havervall S, Rosell A, et al. Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID-19. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):988–994. doi: 10.1161/ATVBAHA.120.315267
   PubMed Web of Science ®Google Scholar
• Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 Jun;7(6):e438–e440. doi: 10.1016/S2352-3026(20)30145-9
   PubMed Web of Science ®Google Scholar
• Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID/Post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021 Aug 23;20(1):172. doi: 10.1186/s12933-021-01359-7
   PubMed Web of Science ®Google Scholar
• Zuin M, Engelen MM, Barco S, et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis. Thromb Res. 2022 Jan;209:94–98.
   PubMed Web of Science ®Google Scholar
• Lessiani G, Boccatonda A, D’Ardes D, et al. Mondor’s disease in SARS-CoV-2 infection: a Case of superficial vein thrombosis in the era of COVID-19. Eur J Case Rep Intern Med. 2020;7(10):001803. doi: 10.12890/2020_001803
   PubMedGoogle Scholar
• Ranucci M, Baryshnikova E, Anguissola M, et al. The long term residual effects of COVID-Associated coagulopathy. Int J Mol Sci. 2023 Mar 14;24(6):5514. doi: 10.3390/ijms24065514
   PubMed Web of Science ®Google Scholar
• von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021 Feb 9;5(3):756–759. doi: 10.1182/bloodadvances.2020003968
   PubMed Web of Science ®Google Scholar
• Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020 Nov 13;11(1):5761. doi: 10.1038/s41467-020-19623-x
   PubMed Web of Science ®Google Scholar
• Fan BE, Wong SW, Sum CLL, et al. Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: assessing the long-term outcomes in COVID-19 patients. Am J Hematol. 2022 Jul;97(7):915–923. doi: 10.1002/ajh.26575
   PubMed Web of Science ®Google Scholar
• Kruger A, Vlok M, Turner S, et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022 Sep 21;21(1):190. doi: 10.1186/s12933-022-01623-4
   PubMed Web of Science ®Google Scholar
• Ryu JK, Sozmen EG, Dixit K, et al. SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. bioRxiv. 2021Oct 13. doi: 10.1101/2021.10.12.464152
   Google Scholar
• Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep. 2021 Aug 27;41(8). doi: 10.1042/BSR20210611
   PubMed Web of Science ®Google Scholar
• Kell DB, Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integr Biol (Camb). 2015 Jan;7(1):24–52. doi: 10.1039/c4ib00173g
   PubMed Web of Science ®Google Scholar
• Kell DB, Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Prog Biophys Mol Biol. 2017 Jan;123:16–41. doi: 10.1016/j.pbiomolbio.2016.08.006
   PubMed Web of Science ®Google Scholar
• Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of readily detected amyloid blood clots in ‘unclotted’ type 2 diabetes mellitus and COVID-19 plasma: a preliminary report. Cardiovasc Diabetol. 2020 Nov 17;19(1):193. doi: 10.1186/s12933-020-01165-7
   PubMed Web of Science ®Google Scholar
• Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/Post-acute sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022 Aug 6;21(1):148. doi: 10.1186/s12933-022-01579-5
   PubMed Web of Science ®Google Scholar
• Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022 Feb 17;479(4):537–559. doi: 10.1042/BCJ20220016
   PubMed Web of Science ®Google Scholar
• Turner S, Naidoo CA, Usher TJ, et al. Increased levels of inflammatory and endothelial biomarkers in blood of long COVID patients point to thrombotic endothelialitis. Semin Thromb Hemost. 2023 May 19. doi: 10.1055/s-0043-1769014
   Web of Science ®Google Scholar
• Pretorius E, Page MJ, Engelbrecht L, et al. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc Diabetol. 2017 Nov 2;16(1):141. doi: 10.1186/s12933-017-0624-5
   PubMedGoogle Scholar
• Nunes JM, Kruger A, Proal A, et al. The occurrence of hyperactivated platelets and fibrinaloid microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Pharmaceuticals (Basel). 2022 Jul 27;15(8):931. doi: 10.3390/ph15080931
   PubMedGoogle Scholar
• Fox T, Hunt BJ, Ariens RA, et al. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition. Cochrane Database Syst Rev. 2023 Jul 26;7(7):Cd015775. doi: 10.1002/14651858.CD015775
   PubMedGoogle Scholar
• Rolla R, Puricelli C, Bertoni A, et al. Platelets: “multiple choice” effectors in the immune response and their implication in COVID-19 thromboinflammatory process. Int J Lab Hematol. 2021 Oct;43(5):895–906. doi: 10.1111/ijlh.13516
   PubMed Web of Science ®Google Scholar
• Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020 Sep 10;136(11):1317–1329. doi: 10.1182/blood.2020007214
   PubMed Web of Science ®Google Scholar
• Hottz ED, Azevedo-Quintanilha IG, Palhinha L, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020 Sep 10;136(11):1330–1341. doi: 10.1182/blood.2020007252
   PubMed Web of Science ®Google Scholar
• Martins-Gonçalves R, Campos MM, Palhinha L, et al. Persisting platelet activation and hyperactivity in COVID-19 survivors. Circ Res. 2022 Nov 11;131(11):944–947. doi: 10.1161/CIRCRESAHA.122.321659
   PubMed Web of Science ®Google Scholar
• Hoepel W, Chen HJ, Geyer CE, et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med. 2021 Jun 2;13(596). doi: 10.1126/scitranslmed.abf8654
   PubMed Web of Science ®Google Scholar
• Philippe A, Günther S, Rancic J, et al. VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients. Angiogenesis. 2023 Aug 1. doi: 10.1007/s10456-023-09890-9
   Web of Science ®Google Scholar
• Constantinescu-Bercu A, Kessler A, de Groot R, et al. Analysis of thrombogenicity under flow reveals new insights into the prothrombotic state of patients with post-COVID syndrome. J Thromb Haemost. 2023 Jan;21(1):94–100. doi: 10.1016/j.jtha.2022.10.013
   PubMed Web of Science ®Google Scholar
• Mobayen G, Dhutia A, Clarke C, et al. Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis. Res Pract Thromb Haemost. 2021 Aug;5(6):e12582. doi: 10.1002/rth2.12582
   PubMed Web of Science ®Google Scholar
• Khan S, Shafiei MS, Longoria C, et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. Elife. 2021 Dec 6;10. doi: 10.7554/eLife.68563
   Web of Science ®Google Scholar
• Prasannan N, Heightman M, Hillman T, et al. Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv. 2022 Jul 12;6(13):4041–4048. doi: 10.1182/bloodadvances.2021006944
   PubMed Web of Science ®Google Scholar
• Fogarty H, Townsend L, Morrin H, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021 Oct;19(10):2546–2553. doi: 10.1111/jth.15490
   PubMed Web of Science ®Google Scholar
• Santilli F, Marchisio M, Lanuti P, et al. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost. 2016 Aug 1;116(2):220–234. doi: 10.1160/TH16-03-0176
   PubMed Web of Science ®Google Scholar
• Campello E, Radu CM, Duner E, et al. Activated platelet-derived and leukocyte-derived circulating microparticles and the risk of thrombosis in heparin-induced Thrombocytopenia: a role for PF4-bearing microparticles? Cytometry B Clin Cytom. 2018 Mar;94(2):334–341. doi: 10.1002/cyto.b.21507
   PubMed Web of Science ®Google Scholar
• Campello E, Spiezia L, Radu CM, et al. Microparticles as biomarkers of venous thromboembolic events. Biomarker Med. 2016 Jul;10(7):743–755. doi: 10.2217/bmm-2015-0063
   PubMed Web of Science ®Google Scholar
• Campello E, Zanetto A, Spiezia L, et al. Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thromb Res. 2016 Jul;143:118–121.
   PubMed Web of Science ®Google Scholar
• Zahran AM, El-Badawy O, Ali WA, et al. Circulating microparticles and activated platelets as novel prognostic biomarkers in COVID-19; relation to cancer. PLoS One. 2021;16(2):e0246806. doi: 10.1371/journal.pone.0246806
   PubMed Web of Science ®Google Scholar
• Guervilly C, Bonifay A, Burtey S, et al. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Adv. 2021 Feb 9;5(3):628–634. doi: 10.1182/bloodadvances.2020003308
   PubMed Web of Science ®Google Scholar
• Rosell A, Havervall S, von Meijenfeldt F, et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality-brief report. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):878–882. doi: 10.1161/ATVBAHA.120.315547
   PubMed Web of Science ®Google Scholar
• Argañaraz GA, Palmeira JDF, Argañaraz ER. Phosphatidylserine inside out: a possible underlying mechanism in the inflammation and coagulation abnormalities of COVID-19. Cell Commun Signal. 2020 Dec 27;18(1):190. doi: 10.1186/s12964-020-00687-7
   PubMed Web of Science ®Google Scholar
• Althaus K, Marini I, Zlamal J, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021 Feb 25;137(8):1061–1071. doi: 10.1182/blood.2020008762
   PubMed Web of Science ®Google Scholar
• Cappellano G, Raineri D, Rolla R, et al. Circulating Platelet-Derived Extracellular Vesicles Are a Hallmark of Sars-Cov-2 Infection. Cells. 2021 Jan 7;10(1):85. doi: 10.3390/cells10010085
   PubMed Web of Science ®Google Scholar
• Burrello J, Caporali E, Gauthier LG, et al. Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles. Vasc Pharmacol. 2022 Aug;145:106999.
   PubMed Web of Science ®Google Scholar
• Campello E, Radu CM, Simion C, et al. Longitudinal trend of plasma concentrations of extracellular vesicles in patients hospitalized for COVID-19. Front Cell Dev Biol. 2021;9:770463. doi: 10.3389/fcell.2021.770463
   PubMed Web of Science ®Google Scholar
• Luijten D, de Jong CMM, Ninaber MK, et al. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost. 2022 Jul 12;49(08):848–860. doi: 10.1055/s-0042-1749659
   PubMed Web of Science ®Google Scholar
• Cueto-Robledo G, Porres-Aguilar M, Puebla-Aldama D, et al. Severe pulmonary hypertension: an important sequel after severe post-acute COVID-19 pneumonia. Curr Probl Cardiol. 2022 Mar;47(3):101004. doi: 10.1016/j.cpcardiol.2021.101004
   PubMed Web of Science ®Google Scholar
• Boccatonda A, Cocco G, Ianniello E, et al. One year of SARS-CoV-2 and lung ultrasound: what has been learned and future perspectives. J Ultrasound. 2021 Jun;24(2):115–123. doi: 10.1007/s40477-021-00575-x
   PubMed Web of Science ®Google Scholar
• Pizzuto DA, Buonsenso D, Morello R, et al. Lung perfusion assessment in children with long-COVID: a pilot study. Pediatr Pulmonol. 2023 Jul;58(7):2059–2067. doi: 10.1002/ppul.26432
   PubMed Web of Science ®Google Scholar
• Buonsenso D, Di Giuda D, Sigfrid L, et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc Health. 2021 Sep;5(9):677–680. doi: 10.1016/S2352-4642(21)00196-6
   PubMedGoogle Scholar
• Buonsenso D, Morello R, De Rose C, et al. Long-term outcome of a child with postcovid condition: role of cardiopulmonary exercise testing and 24-h holter ECG to monitor treatment response and recovery. Pediatr Pulmonol. 2023 Jun 28;58(10):2944–2946. doi: 10.1002/ppul.26578
   PubMed Web of Science ®Google Scholar
• Moasefi N, Fouladi M, Norooznezhad AH, et al. How could perfluorocarbon affect cytokine storm and angiogenesis in coronavirus disease 2019 (COVID-19): role of hypoxia-inducible factor 1α. Inflamm Res. 2021 Jul;70(7):749–752. doi: 10.1007/s00011-021-01469-8
   PubMed Web of Science ®Google Scholar
• Thachil J. Hypoxia-an overlooked trigger for thrombosis in COVID-19 and other critically ill patients. J Thromb Haemost. 2020 Nov;18(11):3109–3110. doi: 10.1111/jth.15029
   PubMed Web of Science ®Google Scholar
• Evans CE. Hypoxia and HIF activation as a possible link between sepsis and thrombosis. Thromb J. 2019;17(1):16. doi: 10.1186/s12959-019-0205-9
   PubMed Web of Science ®Google Scholar
• Santoro F, Nuñez-Gil IJ, Vitale E, et al. Antiplatelet therapy and outcome in COVID-19: the Health outcome predictive evaluation registry. Heart. 2022 Jan;108(2):130–136. doi: 10.1136/heartjnl-2021-319552
   PubMed Web of Science ®Google Scholar
• Meizlish ML, Goshua G, Liu Y, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. 2021 Apr 1;96(4):471–479. doi: 10.1002/ajh.26102
   PubMed Web of Science ®Google Scholar
• Viecca M, Radovanovic D, Forleo GB, et al. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res. 2020 Aug;158:104950.
   PubMed Web of Science ®Google Scholar
• Chow JH, Rahnavard A, Gomberg-Maitland M, et al. Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19. JAMA Netw Open. 2022 Mar 1;5(3):e223890. doi: 10.1001/jamanetworkopen.2022.3890
   PubMed Web of Science ®Google Scholar
• Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023 Jan 3;329(1):39–51. doi: 10.1001/jama.2022.23257
   PubMed Web of Science ®Google Scholar
• Mohamed-Hussein AAR, Aly KME, Ibrahim MAA. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Med Hypotheses. 2020 Nov;144:109975. doi: 10.1016/j.mehy.2020.109975
   PubMed Web of Science ®Google Scholar
• Homoncik M, Jilma B, Eichelberger B, et al. Inhibitory activity of aspirin on von Willebrand factor-induced platelet aggregation. Thromb Res. 2000 Sep 1;99(5):461–466. doi: 10.1016/S0049-3848(00)00297-8
   PubMed Web of Science ®Google Scholar
• Zhao L, Gray L, Leonardi-Bee J, et al. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets. 2006 Mar;17(2):100–104. doi: 10.1080/09537100500235966
   PubMed Web of Science ®Google Scholar
• Fan M, Xu H, Wang L, et al. Tissue plasminogen activator neurotoxicity is neutralized by recombinant ADAMTS 13. Sci Rep. 2016 May 16;6(1):25971. doi: 10.1038/srep25971
   PubMedGoogle Scholar
• Bradbury CA, Lawler PR, Stanworth SJ, et al. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022 Apr 5;327(13):1247–1259. doi: 10.1001/jama.2022.2910
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Jan 8;399(10320):143–151. doi: 10.1016/S0140-6736(21)01825-0
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022 Dec;10(12):1160–1168. doi: 10.1016/S2213-2600(22)00299-5
   PubMed Web of Science ®Google Scholar
• Matli K, Farah R, Maalouf M, et al. Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. Open Heart. 2021 Jun;8(1):e001628. doi: 10.1136/openhrt-2021-001628
   PubMed Web of Science ®Google Scholar
• Rizk JG, Lavie CJ, Gupta A. Low-dose aspirin for early COVID-19: does the early bird catch the worm? Expert Opin Investig Drugs. 2021 Aug;30(8):785–788. doi: 10.1080/13543784.2021.1950687
   PubMed Web of Science ®Google Scholar
• van der Togt V, McFarland S, Esperti M, et al. Promotion of non-evidence-based therapeutics within patient-led long COVID support groups. Nat Med. 2021 Dec;27(12):2068–2069. doi: 10.1038/s41591-021-01589-y
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Serban C, Ursoniu S, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016 Mar;115(3):520–532. doi: 10.1160/th15-08-0620
   PubMed Web of Science ®Google Scholar
• de Kruif MD, Lemaire LC, Giebelen IA, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007 Feb 1;178(3):1845–1851. doi: 10.4049/jimmunol.178.3.1845
   PubMed Web of Science ®Google Scholar
• Fröhlich GM, Jeschke E, Eichler U, et al. Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. Clin Res Cardiol. 2021 Jul;110(7):1041–1050. doi: 10.1007/s00392-020-01783-x
   PubMed Web of Science ®Google Scholar
• Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, et al. Practical recommendations for optimal thromboprophylaxis in patients with COVID-19: a consensus Statement based on available clinical trials. J Clin Med. 2022 Oct 11;11(20):5997. doi: 10.3390/jcm11205997
   PubMed Web of Science ®Google Scholar
• Zhai Z, Li C, Chen Y, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus Statement before guidelines. Thromb Haemost. 2020 Jun;120(6):937–948. doi: 10.1055/s-0040-1710019
   PubMed Web of Science ®Google Scholar
• Schulman S, Sholzberg M, Spyropoulos AC, et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022 Oct;20(10):2214–2225. doi: 10.1111/jth.15808
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Connors JM, Douketis JD, et al. Good practice statements for antithrombotic therapy in the management of COVID-19: guidance from the SSC of the ISTH. J Thromb Haemost. 2022 Oct;20(10):2226–2236. doi: 10.1111/jth.15809
   PubMed Web of Science ®Google Scholar
• Simion C, Campello E, Boccatonda A, et al. POST-discharge thromboprophylaxis in patients with COVID-19: a single-center experience. Intern Emerg Med. 2022 Dec;30:1–6.
   Google Scholar
• Engelen MM, Vandenbriele C, Balthazar T, et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost. 2021 Jun;47(4):362–371. doi: 10.1055/s-0041-1727284
   PubMedGoogle Scholar
• Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022 Jan 1;399(10319):50–59. doi: 10.1016/S0140-6736(21)02392-8
   PubMed Web of Science ®Google Scholar
• Carvalho de Oliveira CC, Agati LB, Ribeiro CM, et al. Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study. Lancet Reg Health Am. 2023 Aug;24:100543.
   PubMedGoogle Scholar
• Dai MF, Xin WX, Kong S, et al. Effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19: a systematic review and meta-analysis. Thromb Res. 2023 Jan;221:105–112. doi: 10.1016/j.thromres.2022.11.019
   PubMed Web of Science ®Google Scholar
• Rauch-Kröhnert U, Puccini M, Placzek M, et al. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial. Clin Res Cardiol. 2023 Jul 5;112(11):1620–1638. doi: 10.1007/s00392-023-02240-1
   PubMed Web of Science ®Google Scholar
• Ismaiel A, Spinu M, Socaciu C, et al. Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis. Nutr Diabetes. 2022 Jan 18;12(1):4. doi: 10.1038/s41387-022-00182-7
   PubMed Web of Science ®Google Scholar
• Arachchillage DJ, Rajakaruna I, Odho Z, et al. Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: multicentre observational study in the UK. Br J Haematol. 2023 Aug;202(3):485–497. doi: 10.1111/bjh.18874
   PubMedGoogle Scholar
• Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv. 2022 Jan 25;6(2):664–671. doi: 10.1182/bloodadvances.2021005945
   PubMed Web of Science ®Google Scholar
• Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and Expert panel report. Chest. 2020 Sep;158(3):1143–1163. doi: 10.1016/j.chest.2020.05.559
   PubMed Web of Science ®Google Scholar